Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease
Wan‐Long Chuang(Kaohsiung Medical University), Alessandra Mangia(Casa Sollievo della Sofferenza), Marianne Camargo(Gilead Sciences (United States)), Brian J. Kirby(Meta (United States)), Hadas Dvory‐Sobol(Gilead Sciences (United States)), Chen‐Hua Liu(National Taiwan University Hospital), Luigi Biancone(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Tsung‐Hui Hu(National Sun Yat-sen University), Meghan E. Sise(Harvard University), Sophia Lu(Myovant Sciences (United States)), Cheng‐Yuan Peng(China Medical University), Wei‐Wen Su(Taichung Veterans General Hospital), Christophe Moreno(Genfit (France)), Peter Buggisch(Institute for Interdisciplinary Medicine), Anu Osinusi(Gilead Sciences (United States)), Robert H. Hyland(Gilead Sciences (United States)), Anuj Gaggar(Gilead Sciences (United States))
Cited by 11
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k